title: Antidepressant-type effect of the NK3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity.
abstract: The influence of the tachykinin NK3 receptor agonist, aminosenktide on the immobility in the forced swimming test was studied in mouse lines selectively bred for divergent magnitudes of stress-induced analgesia. The high analgesia (HA) line is known to display enhanced, and the low analgesia (LA) line displays reduced activity of the opioid system. Aminosenktide at doses of 125 microg/kg or 250 microg/kg intraperitoneally (IP) reduced, in naltrexone-reversible manner, the immobility more of opioid receptor-dense HA than of unselected mice, but was ineffective in the opioid receptor-deficient LA line. The effect of aminosenktide was quite similar to the antiimmobility action of desipramine (10 mg/kg IP), a prototypic antidepressant agent. None of the compounds increased animals' locomotion as found with an open field test; therefore their antiimmobility effect cannot be attributed to a change in general motility. The results claim that aminosenktide causes an antidepressant effect, and endogenous opioids are involved in this process.
authors.affiliation: Department of Pharmacology and Toxicology, Military Institute of Hygiene and Epidemiology, 01-163 4 Warsaw, Kozielska, Poland. ipanocka@wihe.waw.pl
authors.forename: I
authors.initials: I
authors.lastname: Panocka
authors.forename: M
authors.initials: M
authors.lastname: Massi
authors.forename: I
authors.initials: I
authors.lastname: Lapo
authors.forename: T
authors.initials: T
authors.lastname: Swiderski
authors.forename: M
authors.initials: M
authors.lastname: Kowalczyk
authors.forename: B
authors.initials: B
authors.lastname: Sadowski
mesh_terms: D000698:Analgesia; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D005260:Female; D007213:Indomethacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D051379:Mice; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009294:Narcotics / Q000378:metabolism*; D010446:Peptide Fragments / Q000737:chemistry* / Q000494:pharmacology; D018039:Receptors, Tachykinin / Q000737:chemistry*; D013373:Substance P / Q000031:analogs & derivatives / Q000737:chemistry* / Q000494:pharmacology; D013550:Swimming
chemical_list: D000928:Antidepressive Agents; D009294:Narcotics; D010446:Peptide Fragments; D018039:Receptors, Tachykinin; C057852:substance P (5-11), Asp(5,6)-MePhe(8)-; C034674:5-hydroxyindomethacin; D013373:Substance P; C010410:6 beta-hydroxynaltrexone; D009271:Naltrexone; D007213:Indomethacin